(2024, February 19)
If water sounds unappealing, try sugar-free electrolyte drinks or clear broths
According to data from Phase 2 clinical trials, patients reported minor adverse events (AEs) at the following rates [2]: Headaches (11%) Facial flushing (20.4%) Nausea (39.9%) According to the results of a longer phase 3 clinical trial, lasting 52-weeks, patients reported AEs at the following rates [9]: Nausea (40.4%) Headache (12.0%) Flushing (20.6%) The only serious AE to occur during long-term (open-label) PT-141 trials was nausea and it was not severe enough to warrant medical attention [9]
Dual GIP/GLP-1 agonists may be better for patients who havent achieved sufficient weight loss with GLP-1 medications alone, those requiring more aggressive metabolic intervention, individuals who can tolerate the slightly higher side effect rates at maximum doses, and patients seeking the most effective currently available FDA-approved option
1) that contained all expected components were vitrified and imaged by single-particle cryo-EM on a 300 kV Titan Krios, with (oxyntomodulin) or without (exendin-4) a Volta Phase Plate (VPP)
Commonly reported side effects are minimal and might include mild irritation or redness at the injection site
